Literature DB >> 23319586

In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells.

Ulf Dettmer1, Andrew J Newman, Eric S Luth, Tim Bartels, Dennis Selkoe.   

Abstract

Aggregation of α-synuclein (αSyn) in neurons produces the hallmark cytopathology of Parkinson disease and related synucleinopathies. Since its discovery, αSyn has been thought to exist normally in cells as an unfolded monomer. We recently reported that αSyn can instead exist in cells as a helically folded tetramer that resists aggregation and binds lipid vesicles more avidly than unfolded recombinant monomers (Bartels, T., Choi, J. G., and Selkoe, D. J. (2011) Nature 477, 107-110). However, a subsequent study again concluded that cellular αSyn is an unfolded monomer (Fauvet, B., Mbefo, M. K., Fares, M. B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., Eliezer, D., Moore, D. J., Schneider, B., Aebischer, P., El-Agnaf, O. M., Masliah, E., and Lashuel, H. A. (2012) J. Biol. Chem. 287, 15345-15364). Here we describe a simple in vivo cross-linking method that reveals a major ~60-kDa form of endogenous αSyn (monomer, 14.5 kDa) in intact cells and smaller amounts of ~80- and ~100-kDa forms with the same isoelectric point as the 60-kDa species. Controls indicate that the apparent 60-kDa tetramer exists normally and does not arise from pathological aggregation. The pattern of a major 60-kDa and minor 80- and 100-kDa species plus variable amounts of free monomers occurs endogenously in primary neurons and erythroid cells as well as neuroblastoma cells overexpressing αSyn. A similar pattern occurs for the homologue, β-synuclein, which does not undergo pathogenic aggregation. Cell lysis destabilizes the apparent 60-kDa tetramer, leaving mostly free monomers and some 80-kDa oligomer. However, lysis at high protein concentrations allows partial recovery of the 60-kDa tetramer. Together with our prior findings, these data suggest that endogenous αSyn exists principally as a 60-kDa tetramer in living cells but is lysis-sensitive, making the study of natural αSyn challenging outside of intact cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319586      PMCID: PMC3585072          DOI: 10.1074/jbc.M112.403311

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

Authors:  B I Giasson; I V Murray; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

2.  Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease.

Authors:  Xiao Tao; Liang Tong
Journal:  J Biol Chem       Date:  2003-05-21       Impact factor: 5.157

3.  Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.

Authors:  H Shimura; M G Schlossmacher; N Hattori; M P Frosch; A Trockenbacher; R Schneider; Y Mizuno; K S Kosik; D J Selkoe
Journal:  Science       Date:  2001-06-28       Impact factor: 47.728

4.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

5.  Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells.

Authors:  J E Payton; R J Perrin; D F Clayton; J M George
Journal:  Brain Res Mol Brain Res       Date:  2001-11-01

6.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

Authors:  M Hashimoto; E Rockenstein; M Mante; M Mallory; E Masliah
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

7.  Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.

Authors:  Vladimir N Uversky; Jie Li; Pierre Souillac; Ian S Millett; Sebastian Doniach; Ross Jakes; Michel Goedert; Anthony L Fink
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

8.  The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease.

Authors:  Mark A Wilson; Jennifer L Collins; Yaacov Hod; Dagmar Ringe; Gregory A Petsko
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-10       Impact factor: 11.205

9.  Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines.

Authors:  R J Perrin; J E Payton; D H Barnett; C L Wraight; W S Woods; L Ye; J M George
Journal:  Neurosci Lett       Date:  2003-10-02       Impact factor: 3.046

10.  Red blood cells are the major source of alpha-synuclein in blood.

Authors:  Robin Barbour; Kristin Kling; John P Anderson; Kelly Banducci; Tracy Cole; Linnea Diep; Michael Fox; Jason M Goldstein; Ferdie Soriano; Peter Seubert; Tamie J Chilcote
Journal:  Neurodegener Dis       Date:  2008-01-04       Impact factor: 2.977

View more
  107 in total

1.  Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Authors:  Timothy J Collier; Kinshuk R Srivastava; Craig Justman; Tom Grammatopoulous; Birgit Hutter-Paier; Manuela Prokesch; Daniel Havas; Jean-Christophe Rochet; Fang Liu; Kevin Jock; Patrícia de Oliveira; Georgia L Stirtz; Ulf Dettmer; Caryl E Sortwell; Mel B Feany; Peter Lansbury; Lisa Lapidus; Katrina L Paumier
Journal:  Neurobiol Dis       Date:  2017-07-12       Impact factor: 5.996

Review 2.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

3.  FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity.

Authors:  Norifumi Shioda; Yasushi Yabuki; Yuka Kobayashi; Misaki Onozato; Yuji Owada; Kohji Fukunaga
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

4.  Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage.

Authors:  TaeHee Kim; Suresh L Mehta; Balarama Kaimal; Kirsten Lyons; Robert J Dempsey; Raghu Vemuganti
Journal:  J Neurosci       Date:  2016-06-29       Impact factor: 6.167

5.  Cysteine cathepsins are essential in lysosomal degradation of α-synuclein.

Authors:  Ryan P McGlinchey; Jennifer C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

6.  ExPLAining early synucleinopathies.

Authors:  Ulf Dettmer; Tim Bartels
Journal:  Brain       Date:  2015-06       Impact factor: 13.501

7.  Female Sex and Brain-Selective Estrogen Benefit α-Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice.

Authors:  Molly M Rajsombath; Alice Y Nam; Maria Ericsson; Silke Nuber
Journal:  J Neurosci       Date:  2019-08-12       Impact factor: 6.167

8.  Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways.

Authors:  Annadurai Anandhan; Humberto Rodriguez-Rocha; Iryna Bohovych; Amy M Griggs; Laura Zavala-Flores; Elsa M Reyes-Reyes; Javier Seravalli; Lia A Stanciu; Jaekwon Lee; Jean-Christophe Rochet; Oleh Khalimonchuk; Rodrigo Franco
Journal:  Neurobiol Dis       Date:  2014-12-08       Impact factor: 5.996

Review 9.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

10.  KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity.

Authors:  Ulf Dettmer; Andrew J Newman; Victoria E von Saucken; Tim Bartels; Dennis Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.